Novo and Orbis Sign 1.4 Billion Dollar Deal

Orbis Medicines and Novo Nordisk formed a partnership worth up to 1.4 billion dollars to develop oral therapies for cardiometabolic diseases. The collaboration utilizes Orbis artificial intelligence platform to create novel macrocycle drugs.

Xurve View
Insights:
FILE PHOTO: The Novo Nordisk logo on a sign outside its facility in Malov, west of Copenhagen, Denmark, July 31, 2026.

NOVO NORDISK A/S-B partnered with Orbis Medicines on Thursday afternoon in a discovery deal worth up to $1.4 billion for oral cardiometabolic therapies. The collaboration targets a shift from traditional injectables to swallowed macrocycle drugs. The agreement includes upfront fees, milestone payments, and tiered sales royalties for Orbis alongside a strategic equity investment from the Denmark drugmaker.